Physician profile
James L Eppelbaum
NPI 1558609065
$333.49
in general payments reported to CMS, 2019-2025
10 companies · $53.74 in 2025
The $53.74 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.83 · 2021: $22.83 · 2022: $106 · 2023: $13.06 · 2024: $91.47 · 2025: $53.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $85.86 | 2022-2024 | Xarelto |
| Novo Nordisk INC | $56.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $56.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.53 | 2019-2025 | Jardiance |
| Abbvie INC. | $22.83 | 2021 | |
| Lilly USA, LLC | $20.89 | 2022 | |
| Neurocrine Biosciences, INC. | $17.99 | 2025 | |
| Merck Sharp & Dohme LLC | $13.54 | 2022 | |
| Glaxosmithkline, LLC. | $12.42 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.18 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Eppelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.